Glenmark Pharmaceuticals Receives US FDA Approval for Progesterone Vaginal Inserts, Strengthens Women’s Health Portfolio
perigon
Last updated: April 18, 2026
Glenmark Pharmaceuticals Limited has secured final USFDA approval for its Progesterone Vaginal Inserts, 100 mg. This approval signifies a crucial step in expanding their product portfolio and addressing specific medical needs within the United States market.
- Glenmark's Progesterone Vaginal Inserts, 100 mg, have received the USFDA's final approval. This marks a significant development for the pharmaceutical company, allowing for the marketing and distribution of this product in the United States. The approval is based on Glenmark's submission of a Abbreviated New Drug Application (ANDA). The drug is indicated for use in women who require supplementation or replacement of the luteal function in fertility or early pregnancy. This product is a generic version of Crinone Vaginal Gel, 8%. The approval is a testament to Glenmark's robust research and development capabilities and its commitment to expanding its women's health portfolio. The company anticipates launching the product in the US market in the near future. This move aligns with Glenmark's strategy to strengthen its presence in key regulated markets like the United States. The economic impact for Glenmark includes potential revenue generation from sales of this new product, contributing to its overall financial performance. This regulatory milestone is critical for Glenmark's growth trajectory in the US pharmaceutical landscape.
